U.S. Water Utilities Stock News

Fastenal (FAST) just posted its Q1 2026 scorecard, with recent quarterly numbers showing Q4 2025 revenue of about US$2.0b and basic EPS of US$0.26, alongside trailing twelve month basic EPS of US$1.10 on revenue of roughly US$8.2b. The company has seen revenue move from US$1.82b in Q4 2024 to about US$2.03b in Q4 2025, while quarterly basic EPS shifted from US$0.23 to US$0.26 over the same period, setting up this latest report against a backdrop of steady top line and per share earnings. With...

Representative April McClain Delaney recently bought shares of Martin Marietta Materials (NYSE:MLM). The transaction involves a sitting member of Congress, drawing attention to the company and its current valuation. The purchase comes as Martin Marietta Materials trades around $635.29 per share. Martin Marietta Materials, trading on the NYSE under the ticker MLM, sits at a share price of about $635.29. The stock has returned 6.2% over the past week, 8.8% over the past month, and 27.0% over...

In late March 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, incorporating both the Catalent Indiana facility and a second U.S.-based fill-finish site in line with recent agency guidance. This resubmission, following a prior Complete Response Letter tied to manufacturing inspections rather than apitegromab itself, shifts regulatory focus back to the drug’s clinical profile and supply-chain readiness...

Ecovyst recently reported quarterly earnings that came in ahead of analyst expectations and issued full-year 2026 EPS guidance in the US$0.45–US$0.65 range, prompting several brokerages to reaffirm or upgrade their views on the company’s outlook. This combination of an earnings beat and clearer profit guidance has sharpened the focus on how Ecovyst’s fundamentals align with assessments that its shares may be trading at a premium to intrinsic value. We’ll now explore how Ecovyst’s...

In April 2026, Natera highlighted interim futility analysis from Allogene Therapeutics’ registrational ALPHA3 trial, where its off‑the‑shelf anti‑CD19 CAR T candidate cema‑cel achieved molecular residual disease clearance in a majority of treated large B‑cell lymphoma patients and showed deep reductions in plasma ctDNA compared with observation alone. Because ALPHA3 is the first MRD‑guided randomized trial in this lymphoma setting, these early data not only support cema‑cel’s potential role...

Foresight Financial Group (FGFH) has just posted Q4 2025 numbers that cap off a softer year, with total revenue of US$3.3 million, basic EPS of US$0.70 and trailing twelve month revenue of US$46.5 million translating into EPS of US$2.18. Over the past year, total revenue on a trailing basis moved from US$49.5 million in Q4 2024 to US$46.5 million in Q4 2025 while trailing EPS went from US$3.61 to US$2.18, setting the scene for a story where margins and earnings quality sit firmly in...

Marti Technologies (NYSEAM:MRT) has opened FY 2025 with first half revenue of US$14.3 million and a basic EPS loss of US$0.26, setting a cautious tone for investors watching the company’s path toward better profitability. The business has seen revenue move from US$8.4 million in the first half of 2024 to US$10.3 million in the second half of 2024 and then to US$14.3 million in the latest half, while EPS losses shifted from US$0.38 to US$0.87 and now US$0.26. As a result, the market will be...

If you are wondering whether Valmont Industries at around US$432 a share still offers value, or if most of the opportunity is already reflected in the price, this article walks through the key clues for you. The stock has recently shown strong returns, with 7.1% over the last week, 5.5% over the last month, 4.9% year to date, 53.4% over the past year, 47.3% over three years, and 90.8% over five years. Recent headlines have focused on Valmont Industries as part of broader conversations around...

Kilroy Realty (NYSE:KRC) released its 15th annual Sustainability Report. The report highlights continued carbon neutral operations for the sixth consecutive year. KRC also reported multiple industry recognitions, including the 2026 Nareit Leader in the Light Award. Kilroy Realty, a real estate investment trust focused on office and mixed use properties, is putting its latest sustainability update in front of investors at a time when environmental and social factors are drawing more...

Box (NYSE:BOX) has launched Box Agent, a unified AI engine now generally available across its content platform. The company also introduced upgrades to Box AI Studio, allowing enterprises to build and deploy custom AI agents and workflows. These releases focus on automating complex unstructured content tasks while keeping data within Box’s security and compliance controls. Box is rolling out these AI capabilities at a time when its share price stands at $22.35, with a 1-year return of a...

ADS-TEC Energy (NasdaqCM:ADSE) has opened FY 2025 with first half revenue of €14.6 million and a basic EPS loss of €0.27, alongside a net income loss of €14.8 million. These figures put fresh numbers around a business that is still working through heavy investment and margin pressure. Over recent periods the company has reported revenue of €79.3 million in 1H 2024, €30.8 million in 2H 2024 and €14.6 million in 1H 2025, while basic EPS remained in loss territory at €0.89, €1.02 and €0.27...

Sify Technologies (NasdaqCM:SIFY) has just laid out a tough FY 2026 picture, with Q3 revenue of ₹11.6b and a net loss of ₹329m, alongside a trailing twelve month net loss of ₹1.57b that keeps profitability firmly under pressure. Over recent quarters, the company has seen revenue move from ₹9.7b in Q4 FY 2025 to ₹10.7b in Q1 FY 2026, ₹10.5b in Q2 and ₹11.6b in Q3. Over the same period, EPS has shifted from a profit of ₹1.98 in Q2 FY 2025 to losses of ₹7.97 in Q4 and ₹3.78 in Q2 FY 2026. This...

ALT5 Sigma (NasdaqCM:ALTS) has just posted a sharp swing in its FY 2025 third quarter numbers, with total revenue at US$7.6 million and Basic EPS at US$0.64, backed by net income from continuing operations of US$46.7 million and earnings from discontinued operations of US$2.3 million. Over recent quarters the company has seen revenue move from US$4.9 million in FY 2024 Q3 to US$5.4 million in Q4, US$5.5 million in FY 2025 Q1 and US$6.4 million in Q2. Quarterly EPS has ranged from a loss of...

In early April 2026, RPM International Inc. reported fiscal third-quarter 2026 results showing sales of US$1,607.95 million and net income of US$51.36 million, reaffirmed its outlook for mid-single-digit fourth-quarter sales growth versus prior-year records, announced leadership changes in its Consumer Group, and declared a regular US$0.54 quarterly dividend. The earnings beat, driven by record sales and efficiency gains across key segments, has sharpened investor focus on how RPM’s cost...

Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.

The United States market has been on an upward trajectory, climbing 3.1% in the past week and 27% over the last year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying stocks that combine strong fundamentals with growth potential can uncover promising opportunities for investors seeking to enhance their portfolios.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a remarkable 27% increase over the past year, with earnings expected to grow by 16% annually in the coming years. In such a dynamic environment, reliable dividend stocks that offer attractive yields can provide investors with both income and potential growth opportunities.

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks in children aged 2–11, with no serious or treatment-related adverse events. The trial, now the largest pediatric hereditary angioedema study and completed enrollment a year early, highlights strong clinical interest in a first-in-class oral option for a population currently limited to...

If you are wondering whether Magnite's current share price reflects its true worth, this breakdown will help you separate price from value. With the stock at US$11.98, recent returns have been mixed, including a 1.5% decline over 7 days, a 0.8% gain over 30 days, a 25.4% decline year to date, and a 23.8% gain over 1 year, while the 5 year return sits at a 66.8% decline. These moves sit against a longer track record that includes a 24.4% gain over 3 years, which can shape how investors think...

Phase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, a material update that reshapes how you might look at the stock. See our latest analysis for Viridian Therapeutics. The REVEAL-1 update lands after a volatile stretch, with the share price at $14.95, a 7 day share price return of 7.55% but a 90 day share price return of 53.27%,...

What recent returns say about Freedom Holding Freedom Holding (FRHC) has drawn attention after a recent share price move, with the stock showing a 0.2% decline over the past day but double digit gains over the past month. See our latest analysis for Freedom Holding. Putting the recent move in context, Freedom Holding’s 30 day share price return of 14.28% and year to date gain of 21.42%, alongside a 5 year total shareholder return of 205.72%, indicate that momentum has been building over both...

The United States market has shown robust performance, rising 3.1% over the last week and climbing 27% in the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that are perceived as undervalued can be particularly appealing, especially when insider actions suggest confidence in their potential.

The United States market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors seeking to capitalize on discrepancies between current stock prices and their intrinsic values.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a robust 27% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, identifying growth companies with strong insider ownership can be key as it often signals confidence in their long-term potential and alignment of interests between management and shareholders.